Hypercholesterolemia at a young age
https://doi.org/10.52727/2078-256X-2021-17-2-83-93
Abstract
In the present review the analysis of the world literature devoted to the problem of familial hypercholesterolemia at a young age was carried out. Its prevalence both on the territory of the Russian Federation and on the territory of the whole world is discussed. The problem of increased risk of age-dependent cardiovascular events is analyzed. The results of research examining the effectiveness of existing risk assessment scales at a young age, as well as the phenotypic diagnostic criteria, including DLCNC, Simon Broome, MEDPED and Japanese criteria are presented. An overview of studies aimed at investigation of the drug and non-drug therapy positive effect on cholesterol levels is given. Innovative methods of hypercholesterolemia correction were announced. The information on the topic from publications based on PubMed and Google Scholar data were used.
About the Authors
A. N. Spiridonov
Research Institute of Internal and Preventive Medicine – Branch of Federal Research Center Institute of Cytology and Genetics of SB RAS
Russian Federation
Russian Federation
630089, Novosibirsk, Boris Bogatkov str., 175/1
Yu. I. Ragino
Research Institute of Internal and Preventive Medicine – Branch of Federal Research Center Institute of Cytology and Genetics of SB RAS
Russian Federation
Russian Federation
630089, Novosibirsk, Boris Bogatkov str., 175/1
References
1. Ridker P.M., Cook N.R. Cholesterol evaluation in young adults: absence of clinical trial evidence is not a reason to delay screening. Ann. Intern. Med., 2017; 166 (12): 901–902. doi: 10.7326/M17-0855
2. Moradi A., Maleki M., Ghemmaghami Z., Khajali Z., Noohi F., Moghadam M.H., Malakootian M. Mutational spectrum of LDLR and PCSK9 genes identified in Iranian patients with premature coronary artery disease and familial hypercholesterolemia. Front. Genet., 2021; 12: 64–76. doi: 10.3389/fgene.2021.625959
3. Doi T., Hori M., Harada-Shiba M., Kataoka Y., Onozuka D., Nishimura K., Yasuda S. Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia. J. Am. Heart. Assoc., 2021; 10: 1–11. e018263. doi: 10.1161/jaha.120.018263
4. Hori M., Takahashi A., Son C., Ogura M., HaradaShiba M. The first Japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c. 10580 G> A: p.(Arg3527Gln). J. Clin. Lipidol., 2020; 14 (4): 482–486. doi: 10.1016/j.jacl. 2020.05.007
5. Smolina M.O., Benimetskaya K.S., Ragino Yu.I., Voevoda M.I. PCSK9: new victories and horizons. Aterosklero, 2018; 14 (3): 70–77. (In Russ.) doi: 10.15372/ater20180311
6. El Khoury P., Elbitar S., Ghaleb Y., Abou Khalil Y., Varret M., Boileau C., Abifadel M. PCSK9 mutations in familial hypercholesterolemia: from a groundbreaking discovery to anti-PCSK9 therapies. Curr. Atheroscler. Rep., 2017; 19 (12): 1–13. doi: 10.1007/s11883-017-0684-8
7. D’Erasmo L., di Costanzo A., Arca M. Autosomal recessive hypercholesterolemia: update for 2020. Curr. Opin. Lipidol., 2020; 31 (2): 56–61. doi: 10.1097/mol.0000000000000664
8. Bagnasco M.S. Familial Hypercholesterolemia. Dyslipidemia: IntechOpen, 2021. doi: 10.5772/intechopen.96031
9. Soutar A.K., Naoumova R.P. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc., Med., 2007; 4 (4): 214–225. doi: 10.1038/ncpcardio0836
10. Yamamoto T., Davis C.G., Brown M.S., Schneider W.J., Casey M.L., Goldstein J.L., Russell D.W. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell, 1984; 39 (1): 27–38. doi:10.1016/0092-8674(84)90188-0
11. Zdorikova M.A., Kazakova T.E., Dimov I.D., Sesorova I.S. Molecular mechanisms of lipid transport from the endoplasmic reticulum to the Golgi complex in the intestinal villus enterocyte. Mezhdunarodnyi zhurnal prikladnykh i fundamental’nykh issledovanii, 2019. 11: 30–34. (In Russ.) https://www.elibrary.ru/item.asp?id=41561757
12. Myant N.B. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis, 1993; 104 (1-2): 1–18. doi: 10.1016/0021-9150(93)90171-P
13. Chaulin A.M., Aleksandrov A.G., Aleksandrova O.S., Duplyakov D.V. The role of proprotein convertase subtilisin / kexin type 9 (pcsk9) in the pathophysiology of atherosclerosis. Meditsina v Kuzbasse, 2019; 18: 5–15. (In Russ.) https://cyberleninka.ru/article/n/rol-proprotein-konvertazy-subtilizin-keksintipa-9-pcsk9-v-patofiziologii-ateroskleroza/viewer
14. Ding Z., Pothineni N.V.K., Goel A., Lüscher T.F., Mehta J.L. PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovasc. Res., 2020; 116 (5): 908–915. doi: 10.1093/cvr/cvz313
15. Nordestgaard B.G., Chapman M.J., Ray K., Borén J., Andreotti F., Watts G.F., Tybjærg-Hansen A. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur. Heart. J., 2010; 31 (23): 2844–2853 doi: 10.1093/eurheartj/ehq386
16. Bucholz E.M., Rodday A.M., Kolor K., Khoury M.J., de Ferranti S.D. Prevalence and predictors of cholesterol screening, awareness, and statin treatment among US adults with familial hypercholesterolemia or other forms of severe dyslipidemia (1999–2014). Circulation, 2018; 137: 2218–2230. doi: 10.1161/circulationaha.117.032321
17. de Ferranti S.D., Rodday A.M., Mendelson M.M., Wong J.B., Leslie L.K., Sheldrick R.C. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation, 2016; 133: 1067–1072. doi: 10.1161/circulationaha.115.018791
18. Mortensen M.B., Kulenovic I., Klausen I.C., Falk E. Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: Prevalence, risk factor burden, and impact on age at presentation. J. Clin. Lipidol., 2016; 10 (5): 1145–1152. doi: 10.1016/j.jacl.2016.06.002
19. Khera A.V., Won H.H., Peloso G.M., Lawson K.S., Bartz T.M., Deng X., van Leeuwen E.M., Natarajan P., Emdin C.A., Bick A.G., Morrison A.C., Brody J.A., Gupta N., Nomura A., Kessler T., Duga S., Bis J.C., van Duijn C.M., Cupples L.A., Psaty B., Rader D.J., Danesh J., Schunkert H., Person R., Farrall M., Watkins H., Lander E., Wilson J.G., Correa A., Boerwinkle E., Merlini P.A., Ardissino D., Saleheen D., Gabriel S., Kathiresan S. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J. A. Coll. Cardiol., 2016; 67: 2578–2589. doi: 10.1016/j.jacc.2016.03.520so
20. Metel’skaya V.A., Shal’nova S.A., Deev A.D., Perova N.V., Gomyranova N.V., Litinskaya O.A., Evstifeeva S.E., Artamonova G.V., Gatagonova T.M.,Grinshtein Yu.I., Duplyakov D.V., Efanov A.Yu., Zhernakova Yu.V., Il’in V.A., Libis R.A., Minakov A.V., Nevzorova V.A., Nedogoda S.V., Romanchuk S.A., Rotar’ O.P., Trubacheva I.A., Shlyakhto E.V., Boitsov S.A. Analysis of the prevalence of indicators characterizing the atherogenicity of the lipoprotein spectrum in residents of the Russian Federation (according to the ESSE-RF study). Profilakticheskaya meditsina, 2016; 19 (1): 15–23. (In Russ.) doi: 10.17116/profmed201619115-23
21. Ezhov M.V., Sergienko I.V., Duplyakov D.V., Abashina O.E., Kachkovskii M.A., Shaposhnik I.I., Genkel’ V.V., Gurevich V.S., Urazgil’deeva S.A., Tregubov A.V., Konovalova T.V., Muzalevskaya M.V., Voevoda M.I., Bazhan S.S., Makarenkova K.V., Timoshchenko O.V., Ragino Yu.I., Urvantseva I.A., Kozhokar’ K.G., Sokolov A.A., Boeva O.I., Bolotova E.V., Kushnareva Yu.B., Kuznetsova T.Yu., Korneva V.A., Bogdanov D.Yu., Chichina E.E., Solov’ev V.M., Smolenskaya O.G., Galyavich A.S., Safarova M.S., Popova A.V., Malakhov V.V., Ansheles A.A., Nozadze D.N., Semenova E.E., Rozhkova T.A., Solov’eva E.Yu., Gornyakova N.B., Karpov Yu.A., Kukharchuk V.V. Results of the Russian research program for the diagnosis and treatment of patients with familial hypercholesterolemia. High prevalence, low awareness, poor adherence. Ateroskleroz i dislipidemii, 2017; 2 (27): 5–15. (In Russ.) https://www.elibrary.ru/item.asp?id=29429039
22. Harada-Shiba M., Ako J., Arai H., Hirayama A., Murakami Y., Nohara A., Nakamura M. Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the exploreJ study. Atherosclerosis, 2018; 277: 362–368. doi: 10.1016/j.atherosclerosis.2018.06.856
23. Watts G.F., Gidding S., Wierzbicki A.S., Toth P.P., Alonso R., Brown W.V., Kastelein J.J. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int. J. Cardiol., 2014; 171: 309–324. doi: 10.1016/j.ijcard.2013.11.025
24. Kramer A.I., Trinder M., Brunham L.R. Estimating the prevalence of familial hypercholesterolemia in acute coronary syndrome: a systematic review and meta-analysis. Can. J. Cardiol., 2019; 35 (10): 1322–1331. doi: 10.1016/j.cjca.2019.06.017
25. Myers K.D. Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data. Lancet. Digit. Health., 2019; 1 (8): 393–402. doi: 10.1016/S2589-7500(19)30150-5
26. Neil A., Cooper J., Betteridge J., Capps N., McDowell I., Durrington P., Humphries S.E. Reductions in all-cause, cancer, and coronary mortality in statintreated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart. J., 2008; 29 (21): 2625–2633. doi: 10.1093/eurheartj/ehn422
27. Jacobson T.A., Ito M.K., Maki K.C., Orringer C.E., Bays H.E., Jones P.H., Brown W.V. National lipid association recommendations for patient-centered manage ment of dyslipidemia: part 1–full report. J. Clin. Lipidol., 2015; 9 (2): 129–169. doi: 10.1016/j.jacl.2015.02.003
28. Silva P.R., Jannes C.E., Marsiglia J.D., Krieger J.E., Santos R.D., Pereira A.C. Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia. Atherosclerosis, 2016; 250: 144–150. doi: 10.1016/j.atherosclerosis.2016.05.023
29. Wu H., Forgetta V., Zhou S., Bhatnagar S.R., Paré G., Richards J.B. A Polygenic Risk Score for Low-density Lipoprotein Cholesterol is Associated with Risk of Ischemic Heart Disease and Enriches for Individuals with Familial Hypercholesterolemia. Circ. Genom. Precis. Med., 2020. doi: 10.1161/circgen.120.003106
30. Gidding S.S., Ann Champagne M., de Ferranti S.D., Defesche J., Ito M.K., Knowles J.W., Wierzbicki A.S. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation, 2015; 132 (22): 2167–2192. doi: 10.1161/cir.0000000000000297
31. Liu Z., Peng J., Wang S., Jiang T., Zhang W., Zhang C., Lin J. Percutaneous coronary intervention for a Chinese familial hypercholesterolemia homozygous under the guidance of optical coherence tomography. Atheroscler. Suppl., 2019; 36: 19–23. doi: 10.1016/j.atherosclerosissup.2019.01.004
32. Pang J., Abraham A., Vargas-García C., Bates T.R., Chan D.C., Hooper A.J., Watts G.F. An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia. Atherosclerosis, 2020; 298: 52–57. doi: 10.1016/j.atherosclerosis.2020.03.001
33. Hashimoto T., Minami Y., Kakizaki R., Nemoto T., Fujiyoshi K., Meguro K., Ako J. Achilles tendon thickening is associated with disease severity and plaque vulnerability in patients with coronary artery disease. J. Clin. Lipidol., 2019; 13 (1): 194–200. doi: 10.1016/j.jacl.2018.10.007
34. Katamine M., Minami Y., Hashimoto T., Ako J. Familial hypercholesterolemia and vulnerability of coronary plaque in patients with coronary artery disease. Pract. Lab. Med., 2021; 24: 1–9. doi: 10.1016/j.plabm.2021.e00202
35. Rubba P., Gentile M., Marotta G., Iannuzzi A., Sodano M., de Simone B., Fortunato G. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia. Eur. J. Prev. Cardiol., 2017; 24 (10): 1051–1059. doi: 10.1177/2047487317702040
36. Pérez de Isla L., Alonso R., Mata N., Saltijeral A., Muсiz O., Rubio-Marin P., Mata P. Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler. Thromb. Vasc. Biol., 2016; 36 (9): 2004–2010. doi: 10.1161/atvbana.116.307514
37. Frikke-Schmidt R., Arlien-Søborg P., Thorsen S., Jensen H.K., Vorstrup S. LDL receptor mutations and ApoB mutations are not risk factors for ischemic cerebrovascular disease of the young, but lipids and lipoproteins are. Eur. J. Neurol., 1999; 6 (6): 691–696. doi: 10.1046/j.1468-1331.1999.660691.x
38. Hutter C.M., Melissa A.A., Steve E.H. Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview. Am. J. Epidemiol., 2004; 160 (5): 430–435. doi: 10.1093/aje/kwh238
39. Huxley R.R., Hawkins M.H., Humphries S.E., Karpe F., Neil H.A. Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study. Stroke, 2003; 34 (1): 22–25. doi: 10.1161/01.str.0000047123.14312.3e
40. Kaste M., Koivisto P. Risk of brain infarction in familial hypercholesterolemia. Stroke, 1988; 19 (9): 1097–1100. doi: 10.1161/01.str.19.9.1097
41. Mabuchi H., Miyamoto S., Ueda K., Oota M., Takegoshi T., Wakasugi T., Takeda R. Causes of death in patients with familial hypercholesterolemia. Atherosclerosis, 1986; 61 (1): 1–6. doi: 10.1016/0021-9150(86)90107-3
42. Beheshti S., Madsen C.M., Varbo A., Benn M., Nordestgaard B.G. Relationship of familial hypercholesterolemia and high low-density lipoprotein cholesterol to ischemic stroke: Copenhagen general population study. Circulation, 2018; 138 (6): 578–589. doi: 10.1161/circulationaha.118.033470
43. Wang X., Cai G., Wang Y., Liu R., Xi Z., Li G., Zhou Y. Comparison of long-term outcomes of young patients after a coronary event associated with familial hypercholesterolemia. Lipids. Health. Dis., 2019; 18 (1): 1–7. doi: 10.1186/s12944-019-1074-8
44. Wu W.Y., Biery D.W., Singh A., Divakaran S., Berman A.N., Ayuba G., Blankstein R. Recovery of left ventricular systolic function and clinical outcomes in young adults with myocardial infarction. J. Am. Coll. Cardiol., 2020; 75 (22): 2804–2815. doi: 10.1016/j.jacc.2020.03.074
45. Berman A.N., Biery D.W., Singh A., Wu W.Y., Divakaran S., DeFilippis E.M., Blankstein R. Atherosclerotic cardiovascular disease risk and elevated lipoprotein (a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. Eur. J. Prev. Cardiol., 2020; 1–4. 2047487320931296. doi: 10.1177/2047487320931296
46. Aggarwal A., Srivastava S., Velmurugan M. Newer perspectives of coronary artery disease in young. World. J. Cardiol., 2016; 8 (12): 728–734 doi: 10.4330/wjc.v8.i12.728
47. Hatmi Z.N., Mahdavi-Mazdeh M., Hashemi-Nazari S.S., Hajighasemi E., Nozari B., Mahdavi A. Pattern of coronary artery disease risk factors in population younger than 55 years and above 55 years: a population study of 31999 healthy individuals. Acta. Med. Iran, 2011; 368–374. https://pubmed.ncbi.nlm.nih.gov/21874640/
48. Trinder M., Li X., DeCastro M.L., Cermakova L., Sadananda S., Jackson L.M., Brunham L.R. Risk of premature atherosclerotic disease in patients withmonogenic versus polygenic familial hypercholesterolemia. J. Am. Coll. Cardiol., 2019; 74 (4): 512–522. doi: 10.1016/j.jacc.2019.05.043
49. Nordestgaard B.G., Benn M. Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world? Eur. Heart. J., 2017; 38: 1580–1583. doi: 10.1093/eurheartj/ehx136
50. Sturm A.C., Knowles J.W., Gidding S.S., Ahmad Z.S., Ahmed C.D., Ballantyne C.M. Clinical genetic testing for familial hypercholesterolemia JACC Scientific Expert Panel. J Am. Coll. Cardiol., 2018; 72: 662–680. doi: 10.1016/j.jacc.2018.05.04
51. Tada H., Kawashiri M.A., Nohara A., Inazu A., Mabuchi H., Yamagishi M. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur. Heart. J., 2017; 38: 1573–1579. doi: 10.1093/eurheartj/ehx004
52. Bliznyuk S.A., Bubnova M.G., Ezhov M.V. Familial hypercholesterolemia: the current state of the problem and therapeutic and preventive care. Kardiovaskulyarnaya terapiya i profilaktika, 2020; 19 (5): 247–252. (In Russ.) doi: 10.15829/1728-8800-2020-2532
53. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease:consensus statement of the European Atherosclerosis Society. Eur. Heart. J., 2013; 34 (45): 3478–3490. doi: 10.1093/eurheartj/eht273
54. Huijgen R., Hutten B.A., Kindt I., Vissers M.N., Kastelein J.J. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26 406 individuals tested for genetic FH. Circ. Cardiovasc. Genet., 2012; 5 (3): 354–359. doi: 10.1161/circgenetics.111.962456
55. Korneva V.A., Kuznetsova T.Yu., Tikhova G.P. Variability of low-density lipoprotein cholesterol levels in patients with familial hypercholesterolemia, depending on age and gender, and its significance in the diagnosis of this disease. Ratsional’naya farmakoterapiya v kardiologii, 2017; 13 (1): 36–44. (In Russ.) doi: 10.20996/1819-6446-2017-13-1-36-44
56. Castaсer O., Pintу X., Subirana I., Amor A.J., Ros E., Hernáez Á., Fitу M. Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease. J. Am. Coll. Cardiol., 2020; 76 (23): 2712–2724. doi: 10.1016/j.jacc.2020.10.008
57. Balling M., Afzal S., Varbo A., Langsted A., Davey Smith G., Nordestgaard B.G. VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins. J. Am. Coll. Cardiol., 2020; 76 (23): 2725–2735. doi: 10.1016/j.jacc.2020.09.610
58. Sadykova D.I., Susekov A.V., Leont’eva I.V., Zakirov I.I., Slastnikova E.S., Galimova L.F., Sabirova D.R., Krinitskaya N.V. Disorders of lipid metabolism and thyrotoxicosis. Rossiiskii vestnik perinatologii i pediatrii, 2021; 65 (6): 91–97. (In Russ.) doi: 10.21508/1027–4065–2020–65–6–91–97
59. Semakova A.D., Brykova Ya.I. Assessment of lipid metabolism disorders in patients with chronic kidney disease. Molodezh’, Nauka, Meditsina, 2018; 156–158. (In Russ.) https://elibrary.ru/item.asp?id=37383687
60. Zambon A. Non-high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia. Diabetes Mellitus, 2020; 23 (1): 65–71. (In Russ.) doi: 10.14341/dm10351
61. Ovsyannikova A.K., Shcherbakova L.V., Mustafina S.V., Ragino Yu.I., Denisova D.V., Kuntsevich A.K., Rymar O.D. Lipid profile indicators in young people with newly diagnosed type 2 diabetes mellitus. Ateroskleroz, 2018; 14 (3): 39–44. (In Russ.) doi: 10.15372/ater20180306
62. Akioyamen L.E., Genest J., Chu A., Inibhunu H., Ko D.T., Tu J.V. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. J. Clin. Lipidol., 2019; 13 (1): 15–30. doi: 10.1016/j.jacl.2018.10.012.
63. Naghavi M., Falk E., Hecht H.S., Jamieson M.J., Kaul S., Berman D., Shah P.K. alSHAPE Task Force. From vulnerable plaque to vulnerable patient e part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am. J. Cardiol., 2006; 98: 2–15 doi: 10.1016/j.amjcard.2006.03.002
64. Pérez de Isla L., Alonso R., Mata N. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The safeheart Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation, 2017; 135 (11): 2133–2144. doi: 10.1161/circulationaha.116.024541.
65. Raiko J., Magnussen C.G., Kivimäki M., Taittonen L., Laitinen T., Kähönen M., Juonala M. Cardiovascular risk scores in the prediction of subclinical atherosclerosis in young adults: evidence from the cardiovascular risk in a young Finns study. Eur. J. Prev. Cardiol., 2010; 17 (5): 549–555. doi: 10.1097/hjr.0b013e3283386419
66. Kuller L.H. Prevention of coronary heart disease and the National Cholesterol Education Program. Circulation, 2006; 113: 598–560. doi: 10.1161/circulationaha.105.604595
67. Bhopal R., Fischbacher C., Vartiainen E., Unwin N., White M., Alberti G. Predicted and observed cardiovascular disease in South Asians: application of finrisk, Framingham and SCORE models to Newcastle Heart Project data. J. Public. Health., 2005; 27 (1): 93–100. doi: 10.1093/pubmed/fdh202
68. Ridker P.M., Paynter N.P., Rifai N., Gaziano J.M., Cook N.R. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation, 2008; 118 (22): 2243–2251. doi: 10.1161/circulationaha.108.814251
69. Ridker P.M., Buring J.E., Rifai N., Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. Jama, 2007; 297 (6): 611–619. doi: 10.1001/jama.297.6.611
70. Ketola E., Laatikainen T., Vartiainen E. Evaluating risk for cardiovascular diseases–vain or value? How do different cardiovascular risk scores act in real life. J. Public. Health., 2010; 20 (1): 107–112. doi: 10.1093/eurpub/ckp070
71. McMahan C.A., Gidding S.S., Fayad Z.A., Zieske A.W., Malcom G.T., Tracy R.E., McGill H.C. Risk scores predict atherosclerotic lesions in young people. Arch. Intern. Med., 2005; 165 (8): 883–890. doi: 10.1001/archinte.165.8.883
72. McCrindle B.W. Familial hypercholesterolemia in children and adolescents. Curr. Opin. Lipidol., 2012; 23 (6): 525–531. doi: 10.1097/mol.0b013e3283587522
73. Yachmeneva M.P., Ragino Yu.I. The role of hyperlipidemia and hyperglycemia in the development of coronary heart disease in a young population. Ateroskleroz, 2018; 14 (1): 38–42. (In Russ.) doi: 10.15372/ater20180105
74. Goldstein J.L., Brown M.S. The LDL receptor. Arterioscler. Thromb. Vasc. Biol., 2009; 29 (4): 431–438. doi: 10.1161/atvbaha.108.179564
75. Ference B., Yoo W., Ales I., Mahajan N., Mirowska K.K., Mewada A. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J. Am. Coll. Cardiol., 2012; 60 (25): 2631–2639. doi: 10.1016/j.jacc.2012.09.017
76. Real J.T., Chaves F.J., Martinez-Uso I., GarcíaGarcía A.B., Ascaso J.F., Carmena R. Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. Eur. Heart. J., 2001; 22 (6): 465–471. doi: org/10.1053/euhj.2000.2408
77. Khripunova A.A., Boeva O.I., Dzhanibekova A.R., Krasnov A.Yu., Khripunova I.G. Epidemiology and diagnostic features of familial hypercholesterolemia in the Russian population. Terapiya, 2020; 6 (5): 147–156. (In Russ.) doi: 10.18565/therapy.2020.5.147–156
78. Chubykina U.V., Afanas’eva O.I., Tmoyan N.A., Ezhov M.V. Monitoring and screening programs for patients with familial hypercholesterolemia. Ateroskleroz i dislipidemii, 2020; 11 (2): 43–48. (In Russ.) doi: 10.34687/2219–8202.jad.2020.02.0006
79. Allard M.D., Saeedi R., Yousefi M., Frohlich J. Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort. Lipids. Health. Dis., 2014; 13 (1): 1–7. doi: 10.1186/1476-511X-13-65
80. Al-Rasadi K., Al-Waili K., Al-Sabti H.A., Al-Hinai A., Al-Hashmi K., Al-Zakwani I., Banerjee Y. Criteria for diagnosis of familial hypercholesterolemia: a comprehensive analysis of the different guidelines, appraising their suitability in the Omani Arab population. Oman. Med. J., 2014; 29 (2): 85–91. doi: 10.5001/omj.2014.22
81. Suvorova N.N. Methods for identifying and assessing the risk of complications in hereditary disorders of lipid metabolism in medical practice. Literature review. Kremlevskaya meditsina. Klinicheskii vestnik, 2018; 4: 87–91. (In Russ.) https://www.elibrary.ru/item.asp?id=36716940
82. Ahmad Z.S., Andersen R.L., Andersen L.H., O’Brien E.C., Kindt I., Shrader P., Knowles J.W. US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. J. Clin. Lipidol., 2016; 10 (5): 1223–1229. doi: 10.1016/j.jacl.2016.07.011
83. Gidding S.S., Sheldon A., Neben C.L., Williams H.E., Law S., Zhou A.Y., Kindt I. Patient acceptance of genetic testing for familial hypercholesterolemia in the cascade FH registry. J. Clin. Lipidol., 2020; 14 (2): 218–223. doi: 10.1016/j.jacl.2020.02.001
84. Galimova L.F., Sadykova D.I., Slastnikova E.S., Usova N.Eh. Diagnosis of familial hypercholesterolemia in children: cascade screening from theory to practice. Kardiovaskulyarnaya terapiya i profilaktika, 2020; 19 (3): 191–196. (In Russ.) doi: 10.15829/1728- 8800-2020-2348
85. Yezhov M.V., Bliznyuk S.A., Tmoyan N.A., Rozhkova T.A., Duplyakov D.V., Salchenko V.A., Voyevoda M.I. Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with lipid-lowering therapy underperformance (renessans). Russian Journal of Cardiology, 2019; (5): 7–13. (In Russ.) doi: 10.15829/1560-4071-2019-5-7-13
86. Si J., Li J., Yu C., Guo Y., Bian Z., Millwood I., Lv J. Improved lipidomic profile mediates the effects of adherence to healthy lifestyles on coronary heart disease. Elife, 2021; 10: 1–16. doi: 10.7554/eLife.60999
87. Hu P., Dharmayat K.I., Stevens C.A., Sharabiani M.T., Jones R.S., Watts G.F., Vallejo-Vaz A.J. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and metaanalysis. Circulation, 2020; 141 (22): 1742–1759. doi: 10.1161/circulationaha.119.044795
88. Singh A., Gupta A., Collins B.L., Qamar A., Monda K.L., Biery D., Blankstein R. Familial hypercholesterolemia among young adults with myocardial infarction. J. Am. Coll. Cardiol., 2019; 73 (19): 2439–2450. doi: 10.1016/j.jacc.2019.02.059
89. Langslet G., Bogsrud M.P., Halvorsen I., Fjeldstad H., Retterstøl K., Veierød M.B., Ose L. Long-term followup of young adults with familial hypercholesterolemia after participation in clinical trials during childhood. J. Clin. Lipidol., 2015; 9 (6): 778–785. doi: 10.1016/j.jacl.2015.08.008
90. Brunham L.R., Ruel I., Aljenedil S., Rivière J.B., Baass A., Tu J.V., Brophy J. Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018. Can. J. Cardiol., 2018; 34 (12): 1553–1563. doi: 10.1016/j.cjca.2018.09.005
91. McKay A.J., Hogan H., Humphries S.E., Marks D., Ray K.K., Miners A. Universal screening at age 1–2 years as an adjunct to cascade testing for famili al hypercholesterolaemia in the UK: a cost-utility analysis. Atherosclerosis, 2018; 275: 434–443. doi: 10.1016/j.atherosclerosis.2018.05.047
92. Watts G.F., Gidding S.S., Mata P., Pang J., Sullivan D.R., Yamashita S., Ray K.K. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat. Rev. Cardiol., 2020; 17 (6): 360–377. doi: 10.1038/s41569-019-0325-8
93. Dombalis S., Nash A. The Effect of Statins in Children and Adolescents With Familial Hypercholesterolemia: A Systematic Review. J. Pediatr. Health. Care., 2020. doi: 10.1016/j.pedhc.2020.11.007
94. Daniels S., Caprio S., Chaudhari U., Manvelian G., Baccara-Dinet M.T., Brunet A., Bruckert E. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The odyssey kids study. J. Clinical. Lipidol., 2020; 14 (3): 322–330. doi: 10.1016/j.jacl.2020.03.001
95. Gaudet D., Langslet G., Gidding S.S., Luirink I.K., Ruzza A., Kurtz C., Wiegman A. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: rationale and design of the HAUSER-RCT study. J. Clinical. Lipidol., 2018; 12 (5): 1199–1207. doi: 10.1016/j.jacl.2018.05.007
96. Santos R.D., Ruzza A., Hovingh G.K., Wiegman A., Mach F., Kurtz C.E., Gaudet D. Evolocumab in pediatric heterozygous familial hypercholesterolemia. N. Engl. J. Med., 2020; 383 (14): 1317–1327. doi: 10.1056/nejmoa2019910
97. Frangoul H., Altshuler D., Cappellini M.D., Chen Y.S., Domm J., Eustace B.K., Corbacioglu S. Crispr-Cas9 gene editing for sickle cell disease and β-thalassemia. N. Engl. J. Med., 2021; 384 (3): 252–260. doi: 10.1056/nejmoa2031054
98. Zhao H. In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia. Circulation, 2020; 141 (1): 67–79. doi: 10.1161/circulationaha.119.042476
99. Gupta D., Bhattacharjee O., Mandal D., Sen M.K., Dey D., Dasgupta A., Ghosh D. CRISPR-Cas9 system: A new-fangled dawn in gene editing. Life. Sci., 2019; 232: 15–18. doi: 10.1016/j.lfs.2019.116636
100. Li Y., Teng X., Zhang K., Deng R., Li J. RNA strand displacement responsive CRISPR/Cas9 system for mRNA sensing. Anal. Chem., 2019; 91 (6): 3989–3996. doi: 10.1021/acs.analchem.8b05238
101. Borges J.B. Genomics, epigenomics and pharmacogenomics of Familial Hypercholesterolemia (FHBGEP): A study protocol. Res. Social. Adm. Pharm., 2021; 17 (7): 1347–1355. doi: 10.1016/j.sapharm.2020.10.007
102. Kamalova A.A. Diet for hypercholesterolemia in children. Questions of modern pediatrics. Voprosy sovremennoi pediatrii, 2020; 19 (4): 309–315. (In Russ.) doi: 10.15690/vsp.v19i4.2140
103. Khera A.V. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N. Engl. J. Med., 2016; 375 (24): 2349–2358. doi: 10.1056/nejmoa1605086
104. Defesche J.C., Gidding S.S., Harada-Shiba M., Hegele R.A., Santos R.D., Wierzbicki A.S. Familial hypercholesterolaemia. Nat. Rev. Dis. Primers., 2017; 3 (1): 1–20. doi: 10.1038/nrdp.2017.93
105. Stein E.A., Dann E.J., Wiegman A., Skovby F., Gaudet D., Sokal E., Kastelein J.J. Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations. J. Am. Coll. Cardiol., 2017; 70 (9): 1162–1170. doi: 10.1016/j.jacc.2017.06.058
106. Bourbon M., Alves A.C., Alonso R., Mata N., Aguiar P., Padrу T., Mata P. Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry. Atherosclerosis, 2017; 262: 8–13. doi: 10.1016/j.atherosclerosis.2017.04.002
107. Leont’eva I.V. Modern strategy for the diagnosis and treatment of familial heterozygous hypercholesterolemia in children. Rossiyskii vestnik perinatologii i pediatrii, 2020; 65 (4): 27–40. (In Russ.) doi: 10.21508/1027-4065-2020-65-4-27-40
108. Ellis K.L., Pang J., Schultz C.J., Watts G.F. New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials. Eur. J. Prev. Cardiol., 2017; 24 (11): 1200–1205. doi: 10.1177/2047487317708890
Review
For citations:
Spiridonov A.N., Ragino Yu.I. Hypercholesterolemia at a young age. Ateroscleroz. 2021;17(2):83-93. (In Russ.) https://doi.org/10.52727/2078-256X-2021-17-2-83-93
Views:
2913
Email this article 